NCT02124213View on ClinicalTrials.gov

A Study To Evaluate D1 Receptor Occupancy (RO) Following Single Dose of PF-06412562 In Healthy Male Volunteers

PHASE1CompletedINTERVENTIONAL
Enrollment

5

Participants

Timeline

Start Date

September 30, 2014

Primary Completion Date

October 31, 2014

Study Completion Date

October 31, 2014

Conditions
Healthy
Interventions
DRUG

30 mg PF-06412562

Subject will receive a single dose of 30 mg PF-06412562

DRUG

PF-06412562

The dose will be selected based on the results obtained for Cohort 1. This Cohort is optional.

DRUG

PF-06412562

"The dose will be selected based on the results obtained for Cohort 1 and Cohort 2.~This Cohort is optional."

Trial Locations (1)

SE- 141 86

Karolinska Trial Alliance (KTA) M62, Huddinge

Sponsors

Lead Sponsor

Pfizer
All Listed Sponsors
lead

Pfizer

INDUSTRY

NCT02124213 - A Study To Evaluate D1 Receptor Occupancy (RO) Following Single Dose of PF-06412562 In Healthy Male Volunteers | Biotech Hunter | Biotech Hunter